Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Mar 15, 2014 (Vol. 34, No. 6)

Primer3web

URL:primer3.ut.ee
  • Many customizable options
  • No in-page help of descriptions (separate help page)

Polymerase Chain Reaction (PCR): the technique we all love to hate. PCR is immensely useful, but notoriously finicky. One of the biggest (and most important) variables that determines the success or failure of the DNA amplification is the design of the oligonucleotide primers. Primer3web is an online primer design tool that allows users to find either an appropriate matching primer (if one primer sequence is already known), or a complete set of primers for a given user-inputted source sequence. The power of the Primer3web tool is the large number of customizable options for the primer design. These options include the usual suspects such as primer length, melting temperature, and product length, but they also include options relating to thermodynamic secondary structure properties (such as template mispriming and self-complementarity), reaction conditions, and customizable penalty weights for the primers.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »